TICKERNERD
Menu
TNYATNYAHealthcare · Biotechnology

TNYA Stock Forecast: Tenaya Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.54
+2.10% on the day

The 6 Wall Street analysts covering Tenaya Therapeutics, Inc. hold a median 12-month price target of $3 — +451.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$122.0M
Ticker Nerd rank
32 / 100
Median analyst target
$3.00
Analysts covering
6
Revenue$1.1M
Operating income−$20.9M
Net income−$43.4M
Free cash flow−$3.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.9%
1M
−17.9%
YTD
−23.6%
1Y
−70.3%
From 52W high
−74.1%
From 52W low
+2.1%
$0.53
$2.10
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TNYA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tenaya Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Size
73
Issuance
61
Growth
54
Quality
34
Revisions
28
Value
25
Volatility
14
Momentum
11

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (11): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TNYA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TNYA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26TNYAHigh $5.00Median $3.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $2.00Median $3.00High $5.00

The green dot is the last close — the median target sits +451.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Chardan CapitalMaintainsBuy$8.00
12 Mar 2026Chardan CapitalMaintainsBuy—
18 Dec 2025Canaccord GenuityMaintainsBuy—
12 Dec 2025Chardan CapitalMaintainsBuy—
12 Dec 2025HC Wainwright & Co.MaintainsBuy—
10 Nov 2025Chardan CapitalMaintainsBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
7 Aug 2025Chardan CapitalMaintainsBuy—
9 May 2025Chardan CapitalMaintainsBuy—
25 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
13 Mar 2025Canaccord GenuityMaintainsBuy—
12 Mar 2025Chardan CapitalMaintainsBuy—
12 Mar 2025Morgan StanleyMaintainsOverweight—
11 Mar 2025HC Wainwright & Co.MaintainsBuy—
3 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—
18 Dec 2024Chardan CapitalMaintainsBuy—
18 Dec 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TNYA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TNYA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Tenaya Therapeutics, Inc. returned −70.3% against +16.2% for the S&P 500, dividends included.

TNYA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26TNYAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TNYA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Tenaya Therapeutics, Inc. (TNYA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.9×

Cheaper than 82% of US stocks

Price / sales
91.4×

Cheaper than 4% of US stocks

Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
−0.6×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
393.3%

Higher than 98% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1882.8%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−121.9%

Higher than 11% of US stocks

Return on assets
−47.9%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Tenaya Therapeutics, Inc. (TNYA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Tenaya Therapeutics, Inc. has a market value of $122.0M and an enterprise value of $45.5M.

  • Revenue in the twelve months to 30 June 2026: $1.3M. The latest quarter grew 393.3% year on year.

  • Net income over the same four quarters: −$103.1M, a −7724.0% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.53.

  • Free cash flow in the twelve months to 30 June 2026: −$52.6M.

  • Shares outstanding: 224.2M.

  • Trailing P/E: −0.9×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Tenaya Therapeutics, Inc. employs 70 people — $19K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

TNYA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TNYATenaya Therapeutics, Inc.$122.0M
32
HURATuHURA Biosciences, Inc.$117.2M
18
VTVTvTv Therapeutics, Inc.$118.5M
77
COYACoya Therapeutics, Inc.$117.1M
64
FHTXFoghorn Therapeutics, Inc.$116.6M
40
HUMAHumacyte, Inc.$120.6M
18
ENGNenGene Therapeutics, Inc.$114.9M
18

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tenaya Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TNYA news & analysis

Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript

Seeking Alpha · 17 Sept 2026neutral

Tenaya Therapeutics presented at the H.C. Wainwright 28th Annual Global Investment Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's business and updates at the investment event.

Why it matters — The conference presentation gives TNYA watchers an opportunity to hear management discuss the company's pipeline and strategy directly with investors.

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

GlobeNewsWire · 14 Sept 2026positive

Tenaya Therapeutics announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to TN-401 for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The designation was supported by positive interim data from the RIDGE-1 Phase 1b/2 clinical trial, which showed reduced arrhythmia burden.

Why it matters — The RMAT designation and positive interim data indicate regulatory and clinical progress for Tenaya's lead candidate, TN-401, which TNYA watchers would follow closely.

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Tenaya Therapeutics announced that company management will host investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is a clinical-stage biotechnology firm focused on developing therapies for heart disease.

Why it matters — Tenaya's participation in these investor conferences gives shareholders and potential investors an opportunity to hear directly from company management about its pipeline and strategy.

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

MarketBeat · 18 Aug 2026positive

Tenaya Therapeutics' Chief Financial Officer Eric Hyllengren said during a Canaccord discussion that the company expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301.

Why it matters — TNYA watchers would care because the fourth-quarter updates could signal the clinical and regulatory progress of the company's lead cardiac gene therapy programs and TN-301.

Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript

Seeking Alpha · 14 Aug 2026neutral

Tenaya Therapeutics presented at Canaccord Genuity's 46th Annual Growth Conference, as covered by Seeking Alpha with a transcript of the presentation. The item reports that the company participated in this investor conference.

Why it matters — A TNYA watcher would care because the company's remarks at a major growth conference can offer insight into its business and strategy.

FAQ

Frequently asked questions about TNYA stock

What is the TNYA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Tenaya Therapeutics, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TNYA stock a buy right now?

Of the 6 analysts covering Tenaya Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tenaya Therapeutics, Inc. 32 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TNYA?

As at 8 Oct 2026, Tenaya Therapeutics, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

Will TNYA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +451.3% from the last close, and Ticker Nerd's factor model ranks Tenaya Therapeutics, Inc. 32 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TNYA stock forecast for 2030?

No analyst covering Tenaya Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TNYA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has TNYA stock performed over the past year?

Tenaya Therapeutics, Inc. returned -70.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tenaya Therapeutics, Inc. do?

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease.

What is the latest news on TNYA?

The most recent item we track (Seeking Alpha, 17 Sept 2026): "Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript". Tenaya Therapeutics presented at the H.C. Wainwright 28th Annual Global Investment Conference, with a transcript of the presentation published on Seeking Alpha. The presentation covered the company's business and updates at the investment event.

Company

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for heart disease. The company’s current pipeline centers on gene therapy programs such as TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, along with TN-301, a small molecule HDAC6 inhibitor being studied for heart failure with preserved ejection fraction. Tenaya Therapeutics also works through integrated platforms in gene therapy, cellular regeneration, and precision medicine to address the underlying drivers of inherited and other cardiovascular conditions. Headquartered in South San Francisco, California, the company serves the healthcare and biotechnology markets through research, discovery, and clinical development of cardiovascular treatments.

CEO Mr. Faraz Ali M.B.A. · 70 employees · United States · https://www.tenayatherapeutics.com